Interventional Cardiology Devices Market Boston Scientific Corporation and Medtronic are the Leading Player
According to the new market research report Interventional Cardiology Devices Market is projected to reach USD 21.2 billion by 2025 from USD 13.8 billion in 2020, at a CAGR of 8.9%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=548
Market growth is driven mainly by the rapid growth in the geriatric
population and the associated increase in the prevalence of coronary
artery diseases, approval of new and advanced products, and the
increasing prevalence of diabetes. High growth in emerging economies
such as China, India, and Brazil are also driving the demand for
interventional cardiology devices. However, the availability of
alternative treatments and product failures and recalls are the major
factors that are expected to restrain the growth of this market during
the forecast period.
The interventional cardiology devices market is highly consolidated in
nature, with a few players offering a variety of products. The major
players operating in this market are Medtronic (US), Boston Scientific
Corporation (US), Abbott (US), Cardinal Health (US), iVascular (Spain),
Edward Lifesinces Corporation (US), B. Braun Melsungen (Germany), Terumo
Corporation (Japan), Biosensors International Group (Singapore), and
BIOTRONIK SE & Co. KG (Germany).
Boston Scientific is the leading player in the interventional cardiology
devices market. The company offers a wide range of guidewires, stents,
catheters, angioplasty balloons, and structural heart devices. In the
last three years, the company has been focusing on expanding its
interventional cardiology portfolio by adopting various organic and
inorganic strategies. Apart from this, the company has a strong presence
in the US. As a result, in 2019, the company registered ~46% of its
total interventional cardiology revenue from the US alone.
Medtronic is the second-leading player in the interventional cardiology
devices market. The company’s wide range of products and good brand
image helps it maintain its leading position in the market. The company
actively adopts organic strategies to gain a competitive edge in the
market. It has launched various interventional cardiology products in
the last few years. Besides this, the company also has a strong presence
in developed economies, such as the US. As a result, in 2019, the
company generated 50% of its total revenue from the US alone.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=548
North America accounted for the largest share of the interventional
cardiology market in 2019. The large share of this segment can primarily
be attributed to the rising incidence of cardiovascular diseases, the
growing geriatric population, and the strong presence of industry
players in the region.
Comments
Post a Comment